YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Browse Top Headlines

Search Text
Start Date
End Date

New Cas9 Molecule Points the Way to Viral Delivery of CRISPR Systems

TODAY | Bio-IT World | A paper published in today's issue of Nature demonstrates that exploring the natural diversity of CRISPR systems could lead the way to new therapeutic tools, as scientists at the Broad Institute successfully edit the genomes of mice using an AAV vector and a new Cas9 molecule derived from Staphylococcus aureus.

How GitHub Apparently Ended Up In The Crosshairs Of Chinese Hackers

| ReadWrite | It involves dissidents hacking ways around the Great Firewall.

Choosing the cloud that’s right for you

| Computerworld | There are degrees of commitment to the cloud, and more than one cloud model to consider.

LifeMap Solutions Teams Up with Mount Sinai on Digital Health

| Bio-IT World | This morning, LifeMap Solutions announced the launch of COPD Navigator, a mobile health app for people living with chronic obstructive pulmonary disease, in a pilot program conducted with Mount Sinai's Icahn Institute for Genomics and Multiscale Biology.

New York Genome Center Launches First LDT, Whole Exome Sequencing

| Bio-IT World News Brief | The New York Genome Center (NYGC) announced today that it has received approval from the New York State Department of Health to offer clinical whole exome sequencing for individuals with constitutional disorders. This is the first laboratory-developed test, or LDT, from the Center to be cleared for clinical diagnostic use.

Horizon Pays $1.1 Billion for Hyperion’s Rare Disease Drugs

| Xconomy | Big buyout for an orphan drug company. Hyperion's two therapies treat urea cycle disorder, and earned the company $113.6 million in 2014.

GigaScience Paper Demonstrates Pathogen Detection on the MinION

| Bio-IT World News Brief | A team of researchers led by Andy Kilianski of Maryland’s Edgewood Chemical Biological Center has published a paper demonstrating the use of the MinION nanopore sequencer to accurately identify strains of bacteria and viruses.

New Crop of Biotechs from Y Combinator

| Tech Crunch | This week marked Demo Day for budding companies incubated in Silicon Valley accelerator Y Combinator, which began putting out feelers for biotech startups last year and is now moving with more confidence into the biomedical field.

Emerald Opens Cloud Lab Facility

| Bio-IT World News Brief | Emerald Therapeutics is opening its first Emerald Cloud Lab (ECL) production facility, ECL-1, in the biotech corridor of South San Francisco. The robotics life sciences laboratory was announced last year, though plans were already underway for a move to South San Francisco. Since then, the company built a new production facility from the ground up and installed over $3 million of scientific instrumentation.  

deCODE Publishes Largest Human Genome Population Study

| Bio-IT World | With a package of four papers published today in Nature Genetics, deCODE genetics presents the largest set of  human genomes from one population, and findings including a set of complete human knockouts, a new timeline for the common Y-chromosome ancestor, and loss-of-function variants that confer Alzheimer’s disease risk.

Systematic Overhaul Recommended for Human Brain Project

| Nature News | An independent committee reviewing the goals and practices of Europe's Human Brain Project (HBP) has substantially sided with critics of the effort, proposing major changes to the HBP's governance and to its central mission of creating a computer simulation of the human brain.

New Online Tool Creates Guide RNAs for CRISPR Gene Editing

| Bio-IT World | Horizon Discovery, a Cambridge, UK-based research supply company with a focus on gene editing experiments, has launched a free online tool to design guide RNA for CRISPR experiments.

CRISPR in the Germline

| Bio-IT World News Brief | There is a renewed urgency to public conversations about the ethics of genome editing, thanks to the emergence of CRISPR, a gene engineering technology so effective and easy to use that scientists are racing to keep up with its potential applications.

The Right Drug the First Time

| Bio-IT World | Scientists in the growing field of pharmacogenetics believe that new DNA tests can protect patients from adverse drug responses and ineffective prescriptions. Yet it's been an uphill battle to convince payers, medical centers, and clinicians to embrace these tests in mainstream medicine.

Ginkgo Bioworks Opens Its Genetic Engineering Foundry

| Bio-IT World News Brief | Ginkgo Bioworks announced this morning that its synthetic biology “foundry,” an 18,000 square foot facility on the Boston waterfront designed to rapidly iterate through new prototypes of genetically modified organisms, is open for business.

23andMe Therapeutics Won't Change Drug Discovery

| Bio-IT World | 23andMe's new drug discovery unit isn't the next disruptive health innovation from Silicon Valley, but it is a good move for a company that should know better than anyone how to turn genetic data into real value.

Tute Genomics Shares Genetic Variants Database on Google Genomics

| Bio-IT World | Google Genomics and Tute Genomics have announced that a Tute database of 8.5 billion annotations of genetic variants is publicly available through Google Genomics. The database will be hosted on Google Genomics, and can be queried at regular Google Genomics query rates.

23andMe Enters The Drug Business Just As Apple Changes It

| Forbes | 23andMe CEO and Founder Anne Wojcicki 23andMe, the Google-backed personal genetics startup, will no longer just sell tests to consumers, or genetic data to pharmaceutical companies. This morning, it announced that it plans to start inventing medicines itself. It's not just talk. The company has hired Richard Scheller, who led drug discovery at Genentech.

Ewan Birney, Rolf Apweiler appointed Joint Directors of EMBL-EBI

| Bio-IT World News Brief | Ewan Birney and Rolf Apweiler have been appointed Joint Directors of the European Molecular Biology Laboratory – European Bioinformatics Institute (EMBL-EBI). They will assume their new roles with effect from 1 July 2015. Professor Dame Janet Thornton steps down after 14 years as the EMBL-EBI director.  

Merck Serono Signs Up with Illumina's Universal Oncology Test

| Bio-IT World News Brief | Illumina has brought another major pharmaceutical partner on board for its Universal Oncology Test program, an effort to build a next-generation sequencing-based gene panel covering all major cancer-related mutations that could be used to select personalized therapies.

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 ,